Cyproterone Acetate + Ethinylestradiol

This medicine combines two hormones in a single daily tablet. Cyproterone acetate is a synthetic progestogen that also blocks the androgen (male hormone) receptor, while ethinylestradiol is a potent synthetic estrogen widely used in combined oral contraceptives ^[1]. Together they suppress ovulation and lower the activity of androgens, which is why the product is used both to prevent pregnancy and to treat conditions driven by androgens ^[1][3]. The combination is sometimes called co-cyprindiol and is marketed under many names, most famously Diane-35 and Dianette ^[1].

Its principal approved use is in women with androgen-sensitive skin problems, especially moderate to severe acne with or without seborrhea, and hirsutism ^[1]. Reviews of the substantial trial literature report that it is highly effective for these symptoms, although improvement in unwanted hair growth typically requires several months of treatment ^[1][4]. It is also widely used in women with polycystic ovary syndrome, where it can address hyperandrogenic skin symptoms, regulate menstrual cycles, and reduce the risk of endometrial overgrowth, while at the same time providing contraception ^[2].

The estrogen and antiandrogen pairing was developed in the 1970s, with the original Diane formulation using a higher estrogen dose and the later Diane-35 version lowering it ^[1]. Cyproterone acetate itself has a long history as an antiandrogen used for conditions ranging from hirsutism and acne to prostate disease ^[4].

A defining concern with this combination is the risk of venous thromboembolism, or blood clots in the veins. Like other combined hormonal contraceptives it raises this risk above baseline, and some analyses have placed it toward the higher end among such products, although the evidence has been debated ^[3]. Because of the clot risk, European regulators restricted its use, recommending it chiefly for androgen-related skin conditions and generally not for contraception alone; it is prescription-only and is not marketed in some countries, including the United States ^[1][2].

Common side effects include menstrual changes, breast tenderness, headache, nausea, mood changes, and reduced libido, in line with other combined pills ^[1]. It is taken as an oral tablet in a cyclic monthly pattern ^[1].

This is a prescription hormonal product and shares the risks of combined pills, but with an even higher chance of venous blood clots, so it is not a first-choice contraceptive. It should be avoided in women with a history of clots, certain migraines, uncontrolled high blood pressure, or a high clot risk, and smoking over age 35 sharply raises the danger. Because of that clot risk, it is usually stopped a few months after acne or hirsutism clears rather than continued indefinitely. Common effects include nausea, breast tenderness, mood changes, headache, and breakthrough bleeding. It must not be used in pregnancy, and active liver disease is a contraindication.

The active antiandrogen in this combination, cyproterone acetate, was first synthesized in 1961 by the German chemist Rudolf Wiechert at Schering AG, and it became one of the earliest clinically useful blockers of the androgen receptor. Recognizing that combining its antiandrogen and progestogen actions with an estrogen could both treat androgen-related skin disease and provide cycle control, Schering developed the fixed-dose product pairing cyproterone acetate with the synthetic estrogen ethinylestradiol.

It was introduced under the brand name Diane, later reformulated at a lower estrogen dose as Diane-35, and marketed in various countries as Dianette and under the generic term co-cyprindiol. Over the following decades it became a widely used treatment for moderate to severe acne, seborrhea, and hirsutism in women, and it is also employed in the management of polycystic ovary syndrome. Because combined hormonal products of this type carry a higher risk of venous blood clots than some other pills, several European regulators reviewed and restricted its use in 2013, reaffirming its role for androgen-related conditions rather than contraception alone.

This combination has a well-established reputation as an effective treatment for the skin and hair manifestations of androgen excess, offering meaningful relief for women troubled by stubborn acne, oily skin, and unwanted hair growth. By attacking the problem on two fronts, blocking the androgen receptor directly while lowering the amount of free, active testosterone in the blood, it addresses the underlying hormonal drivers rather than merely the symptoms.

Many patients also value the added benefit of reliable cycle regulation and contraception, and reviews highlight its positive effect on quality of life and confidence in those with visible androgen-related conditions. It is regarded as a particularly useful option in polycystic ovary syndrome, where hyperandrogenic skin symptoms are common. A balanced view acknowledges that its elevated clot risk means it is generally reserved for these specific indications and prescribed after weighing individual risk factors.